Melanoma Fighter

Article

Chicago - Arginine deiminase, an amino acid degrading enzyme, is safe and has anti-tumor activity in phase I and II investigations of metastatic melanoma, according to Theodore Logan, M.D.

Related Videos
Related Content

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Considerations for Preventing and Addressing Alopecia in Patients With Religious Headwear

September 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Navigating Topical Steroid Withdrawal and Extreme Adverse Reactions to Corticosteroids

September 20th 2023

Frontline Forum Part 3: Improving Basal Cell Carcinoma Management

September 20th 2023

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Considerations for Preventing and Addressing Alopecia in Patients With Religious Headwear

September 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Navigating Topical Steroid Withdrawal and Extreme Adverse Reactions to Corticosteroids

September 20th 2023

Frontline Forum Part 3: Improving Basal Cell Carcinoma Management

September 20th 2023

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Considerations for Preventing and Addressing Alopecia in Patients With Religious Headwear

September 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Navigating Topical Steroid Withdrawal and Extreme Adverse Reactions to Corticosteroids

September 20th 2023

Frontline Forum Part 3: Improving Basal Cell Carcinoma Management

September 20th 2023
© 2023 MJH Life Sciences

All rights reserved.